In: Vivet Therapeutics

Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board
14/06/2018

Paris, 12 June 2018- Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today announced the…

Read More
Vivet Therapeutics named as one of the “Fierce 15” Biothec Companies of 2017 by FierceBiothec
03/10/2017

Vivet Therapeutics is the only European Company that has been chosen as one of the “Fierce 15”, the final fifteen companies... Read More
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
04/05/2017

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases Paris,... Read More